Poly ICLC is an immunostimulant. It is polyinosinic-polycytidylic acid (poly I:C) mixed with the stabilizers carboxymethylcellulose and polylysine. It is under trial for use in cancer.
Poly I:C is a ligand for toll like receptor-3, which usually triggers on the structurally similar double-stranded RNA present in some viruses.
External links
- National Cancer Institute: poly ICLC
References
Zhu X, Nishimura F, Sasaki K, et al. (2007). "Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models". Journal of Translational Medicine. 5: 10. doi:10.1186/1479-5876-5-10. PMC 1802742. PMID 17295916. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1802742 ↩
"Intervention Dynamic Trial Listing Page". National Cancer Institute. 13 June 2017. https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/poly-iclc ↩
Zhu X, Nishimura F, Sasaki K, et al. (2007). "Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models". Journal of Translational Medicine. 5: 10. doi:10.1186/1479-5876-5-10. PMC 1802742. PMID 17295916. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1802742 ↩